PRESS RELEASE published on 03/27/2025 at 19:12, 8 months 8 days ago Informations privilégiées / Communiqué sur comptes, résultats Advicenne annonce ses résultats annuels 2024 avec un chiffre d'affaires en hausse de 9,4% grâce à Sibnayal® en Europe; avancées réglementaires majeures aux Etats-Unis Chiffre D'affaires Résultats Annuels États-Unis Advicenne Sibnayal
PRESS RELEASE published on 03/27/2025 at 19:12, 8 months 8 days ago Inside Information / News release on accounts, results Advicenne reports successful commercial performance of Sibnayal® in Europe, with total product sales up 9.4% to €4.9m. Major strides in US development with NDA filing expected in Q3 2025 Financial Results Advicenne Commercial Performance Sibnayal US Development
BRIEF published on 10/01/2024 at 07:05, 1 year 2 months ago Advicenne Advances in US with Positive FDA Reviews for ADV7103 FDA ADV7103 ATRd Advicenna Cystinuria
BRIEF published on 10/01/2024 at 07:05, 1 year 2 months ago Advicenne progresse aux États-Unis avec des avis positifs de la FDA sur ADV7103 FDA Advicenne ADV7103 ATRd Cystinurie
PRESS RELEASE published on 10/01/2024 at 07:00, 1 year 2 months ago Inside Information / Other news releases Advicenne achieves major milestones in the US with positive FDA opinions on ADV7103, accelerating partnership outlook for commercialization, preparing for clinical development in cystinuria, and seeking commercial partners Commercialization Advicenne ADV7103 Cystinuria FDA Opinions
PRESS RELEASE published on 10/01/2024 at 07:00, 1 year 2 months ago Informations privilégiées / Autres communiqués Advicenne franchit des étapes majeures aux Etats-Unis pour ADV7103 avec des avis favorables de la FDA, ouvrant des opportunités partenariales, simplifiant les démarches réglementaires et cliniques FDA Développement États-Unis Partenaires Advicenne
BRIEF published on 05/15/2024 at 09:07, 1 year 6 months ago Les actionnaires d'Advicenne approuvent les résolutions soutenues par le conseil d'administration lors de l'assemblée générale Assemblée Générale Euronext Croissance Paris Industrie Pharmaceutique Conseille Maladies Rénales Rares
BRIEF published on 05/15/2024 at 09:07, 1 year 6 months ago Advicenne Shareholders Approve Board-Supported Resolutions at General Meeting Euronext Growth Paris Pharmaceutical Industry General Meeting Advicenne Rare Renal Diseases
PRESS RELEASE published on 05/15/2024 at 09:02, 1 year 6 months ago Inside Information / Other news releases Advicenne's Board of Directors' resolutions approved at the Combined General Meeting. Shareholders support all resolutions including financial statements and delegations Board Of Directors Shareholders Financial Statements Combined General Meeting Advicenne
BRIEF published on 05/15/2024 at 08:06, 1 year 6 months ago Advicenne lance un programme de rachat d'actions Marché Financier Rachat D'actions Euronext Growth Advicenne Maladies Rénales
Published on 12/05/2025 at 17:15, 46 minutes ago TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 1 minute ago Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 2 hours 1 minute ago SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 2 hours 16 minutes ago Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme
Published on 12/05/2025 at 15:45, 2 hours 16 minutes ago Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 17:46, 14 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour ago EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 1 hour 35 minutes ago 4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 51 minutes ago Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 17:18, 43 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 43 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 2 hours 50 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 2 hours 50 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 4 hours 2 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
